Vanda Pharmaceuticals (VNDA) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.33 -1.84%
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.14, $0.02 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $70.1 million versus the consensus estimate of $75 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Barnes & Noble Education (BNED) Tops Q1 EPS by 12c
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
